Cancer Clinical Trial
— C4COfficial title:
A Dyadic Approach to Cancer Care: A Feasibility and Efficacy Partner-based Exercise Study
The primary goal of this study will be to assess the feasibility and acceptability of a partner-based 12-week exercise intervention for cancer caregivers and their care recipient. The researchers will also explore the preliminary effectiveness of the exercise program on caregiver burden and physical and psychological health of both the family caregiver and the care recipient.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria (all): - 18+ years - able to perform discontinuous low intensity physical activity at a minimum - able to provide informed written consent in English. Inclusion Criteria (cancer patients/survivors) - are along any stage of the cancer continuum (i.e., pre-treatment, receiving active treatment, and up to 5 years post-treatment) Inclusion Criteria (informal caregivers) - must be currently providing physical and/or psychological support to an adult (+18 years) cancer patient/survivor - not be exceeding current Canadian physical activity guidelines (i.e., 150 minutes of moderate-to-vigorous physical activity per week) Exclusion Criteria (all): - Patients/survivors and caregivers will be excluded from the study if they have any medical conditions that would contraindicate exercise Exclusion Criteria (informal caregivers) - Bereaved caregivers |
Country | Name | City | State |
---|---|---|---|
Canada | Physical Activity and Cancer (PAC) Lab | Halifax | Nova Scotia |
Lead Sponsor | Collaborator |
---|---|
Nova Scotia Health Authority |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment | Participant accrual as defined as the number of eligible participant dyads who consents to participate | Through study completion, about 2 years | |
Primary | Intervention Adherence | Participant program adherence calculated as percentage of exercise sessions completed divided by total number of available exercise sessions over 12-week intervention | Through study completion, about 2 years | |
Primary | Adverse Events | Adverse and serious adverse events will be recorded | Through study completion, about 2 years | |
Primary | Attrition | Participant attrition calculated as percentage of patients who complete 12-week study divided by number who withdraw from study | Through study completion, about 2 years | |
Primary | Participant Satisfaction | Participant satisfaction will be assessed by semi-structured interviews (no min/max) | Post intervention, about 12-weeks after baseline | |
Secondary | Caregiver Burden | Assessed by the 22-item Zarit Burden Interview (ZBI). Responses are scored on a 5-point Likert scale ranging from 0 (never) to 4 (nearly always) with the sum of scores ranging from 0 to 88 (higher scores indicate higher burden) | Pre to post intervention (12-week change) | |
Secondary | Body Mass Index (BMI) | Weight (kg) and height (m) will be used to calculate BMI | Pre to post intervention (12-week change) | |
Secondary | Body Composition | Waist and hip circumference | Pre to post intervention (12-week change) | |
Secondary | Resting heart rate | Resting heart rate | Pre to post intervention (12-week change) | |
Secondary | Resting Blood Pressure | Resting systolic and diastolic blood pressure | Pre to post intervention (12-week change) | |
Secondary | Aerobic Fitness | The 6-minute walk test will be used to assess aerobic capacity | Pre to post intervention (12-week change) | |
Secondary | Upper Body Strength | Grip strength will be measured using a hand-held dynamometer | Pre to post intervention (12-week change) | |
Secondary | Muscular Endurance | Lower body muscular endurance will be assessed using the 30-second sit-to-stand | Pre to post intervention (12-week change) | |
Secondary | Balance | Balance will be assessed using the one-legged stance | Pre to post intervention (12-week change) | |
Secondary | Flexibility | Flexibility will be assessed using the sit-and-reach and shoulder flexibility | Pre to post intervention (12-week change) | |
Secondary | Caregiver Quality of Life | Quality of life will be assessed using the Short-Form Health Survey- SF-36. The SF-36 consists of 36 questions that cover 8 health domains/subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health). The total scale score ranges from 0 to 100 with higher values representing higher quality of life. | Pre to post intervention (12-week change) | |
Secondary | Cancer Patient Quality of Life | Quality of life for cancer patients will be assessed using the Functional Assessment of Cancer Therapy - General survey. The combined 27-item scale provides subscale scores physical (7-items), functional (7-items), emotional (6-items), and social/family (7-items) well-being. The sum of scores on the five domains evaluates a participants' quality of life with higher scores (ranging from 0-108) denoting higher quality of life. | Pre to post intervention (12-week change) | |
Secondary | Cancer Patient Fatigue | Fatigue will be assessed using the 13-item Functional Assessment of Chronic Illness Therapy - Fatigue survey. Scores range from 0-52 with higher scores indicating better functioning/less fatigue | Pre to post intervention (12-week change) | |
Secondary | Self-Reported Physical Activity | Physical activity will be assessed using the Godin Leisure Time Exercise Questionnaire. Total score ranges from 0 to no maximum. | Pre to post intervention (12-week change) | |
Secondary | General Health (EuroQol) 5 Dimension - 5 Level | Mobility, self-care, usual activities, pain/discomfort, anxiety/depression (EuroQol-5Dimension-5Level; EQ-5D-5L); higher scores indicate higher problems (range 0-1) | Pre to post intervention (12-week change) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|